 |
市場調査レポート
薬理ゲノムに関する提携契約Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 |
||||||
| 発行 | Current Partnering, a division of Wildwood Ventures Limited | 商品コード | 230291 | ||||
| 出版日 | ページ情報 | 英文 129 Pages 納期: 即日から翌営業日 |
|||||
| 価格 |
|
||||||
| 薬理ゲノムに関する提携契約 Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 | ||
| 出版日: 2017年02月02日 | ページ情報: 英文 129 Pages |
|
当レポートでは、薬理ゲノム（ファーマコゲノミクス）に関する提携契約動向について分析し、薬理ゲノムに関するビジネス活動の概要、主な契約内容を検証し、実際の契約文書を参照しながら、概略下記の構成でお届けいたします。
※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。
The ‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 ’ report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors.
Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug's efficacy or toxicity.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 300 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of Pharmacogenomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Pharmacogenomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Pharmacogenomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active Pharmacogenomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Pharmacogenomics dealmaking with a brief summary followed by a comprehensive listing of Pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Pharmacogenomics partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of Pharmacogenomics partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Pharmacogenomics partnering company A-Z, deal type definitions and Pharmacogenomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Pharmacogenomics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmacogenomics technologies and products.
‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 ’ provides the reader with the following key benefits:
‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 ’ is intended to provide the reader with an in-depth understanding and access to pharmacogenomic trends and structure of deals entered into by leading companies worldwide.
‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 ’ includes:
In ‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 ’, the available contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The ‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 ’ report provides comprehensive access to available deals and contract documents for over 300 pharmacogenomic deals. Analyzing actual contract agreements allows assessment of the following:
